Just wrapped a 3D animation for Spyre Therapeutics showing how their TL1A targeting mechanism works at the molecular level — blocking TL1A to dampen immune signaling and promote tissue healing in conditions like rheumatoid arthritis, psoriatic arthritis, and IBD. What is special about this animation: we combined cinematic storytelling with science-accurate molecular simulations to make the biology behind SPY072 and SPY002 feel both real and compelling! Spyre Therapeutics build scientific breakthroughs. Visual Science makes them standout. #Bringscientificbreakthroughstolife

While they are inexpensive to generate, polyclonal antibodies have significant drawbacks that can put your research at risk. From poor characterization to supply limitations, polyclonal antibodies can be a major liability in your assay. In a recent case study, we performed polyclonal antibody sequencing on a rabbit polyclonal used in neurodegenerative disease research. By converting the polyclonal into recombinant monoclonal antibodies, the researchers were able to continue their important work without having to worry about losing an important reagent.

Capturing the immune system’s earliest signal of cancer: autoantibodies as early biomarkers Early detection still struggles with lesion-centric approaches and high follow-up burden. Autoantibodies, immune responses to tumor antigens such as p53, SOX2, NY-ESO-1 and MAGE family proteins, can appear early and persist, offering a biologically meaningful signal for screening and longitudinal monitoring. Prospective, multi-center studies in the field demonstrate translational potential for autoantibody-based approaches. How Absea helps assay teams: - Provides high-purity human recombinant proteins, covering key lung and breast cancer autoantibody targets. - Ensures batch stability and operates a strict quality control system to maintain reagent consistency suitable for IVD development. - Utilizes a mature expression and purification platform combined with a systematic protein resource library that offers broad target coverage to support antigen selection, assay optimization, and scale-up. For assay development or validation, Absea offers reagents with documented batch stability and strict quality control. Contact us at info@abseabio.com for details. #TumorAutoimmunity #CancerBiomarkers #IVDDevelopment #Proteomics 

What if one antibody could take on two targets at once? Bi-specific antibodies (bsAbs) are redefining what’s possible in immunotherapy, designed to bind two different targets simultaneously for unmatched precision. 🔵 Dual-targeting power: Redirects immune cells to attack tumors with greater accuracy. 🔵 Expanding applications: From oncology to autoimmune and infectious diseases, bsAbs are driving next-generation therapies. 🔵  Real-world impact: No longer just the future, bsAbs are already delivering measurable results.  🔵 End-to-end expertise: At Fusion Antibodies, our scientists support every stage of bi-specific development, from discovery and design to engineering and supply.    Get in touch to discuss your next bi-specific program.    #FAB #Bispecifics #Immunotherapy #Therapeutics #Oncology #FusionAntibodies #Biotech #Innovation #Therapeutics #Drugdiscovery #Antibody  

Introducing Plasmapheresis: Advanced Therapy Now Available at Clínica Planas We are proud to announce the arrival of our state-of-the-art plasmapheresis machine—empowering our clinical team to deliver the latest in personalized, science-driven regenerative and immune therapies. Plasmapheresis, also known as therapeutic plasma exchange (TPE), is an innovative procedure that selectively removes and replaces plasma, the component of blood responsible for carrying antibodies, inflammatory mediators, and disease-causing proteins. This technology allows rapid elimination of harmful substances, autoantibodies, and toxins, providing targeted treatment for autoimmune, neurological, hematological, and transplant-related conditions.

#AutoImmunity | #Inflammation | The anti-#Inflammatory activity of #IgG is enhanced by co-engagement of Type I & II #Fc Receptors | MAJOR ADVANCE for #IVIG Therapy | Breaking at Science Magazine | Jeffrey Ravetch & Co. | Autoimmune diseases can be treated by intravenous immunoglobulin (IVIG), a therapeutic that requires substantial quantities of antibodies to be collected from large numbers of healthy human donors. Based on one proposed mechanism of action for IVIG, Andrew Jones, et al*. produced an antibody tail fragment known as the Fc region and modified it so that it inhibited pathology in mouse modals of autoimmunity with a lower dose than IVIG. This engineered Fc protein was modified by sialylation and contained mutations that increased its interaction with a type I receptor known as FcγRIIB. The interaction between FcγRIIB and another receptor, DC-SIGN, promoted the binding of isolated Fc fragments and antibodies to cells. [Courtesy of Sarah Ross]. *https://lnkd.in/etyqSfNw Celentyx Ltd www.celentyx.com Professor Nicholas Barnes PhD, FBPhS Omar Qureshi Catherine Brady GRAPHICAL SUMMARY

🎓 ICYMI 🎓 Discoveries from our proprietary B-cell platform technology and antibody screening approach are featured in a recent peer-reviewed publication in Elsevier’s Science Direct. ✒The paper explores the latest advances in tumor-targeting antibodies, the challenges in the field, and the growing importance of tumor-associated carbohydrate antigens (TACAs) as key immunological targets due to their overexpression in malignant cells. Authored by Edward Meier and Andreas Laustsen-Kiel from the Department of Biotechnology and Biomedicine at DTU - Technical University of Denmark, read the full peer-reviewed publication here: https://lnkd.in/e--Xe5uF 💡Why B-cells? As the natural source of #antibodies, B-cells are uniquely suited for therapeutic discovery. At Kling Biotherapeutics, our proprietary primary B-cell platform enables functional screening and immortalization of patient-derived B-cells, unlocking novel, disease-relevant antibodies and antigens often missed by other methods. 🔍 Dive into our platforms: #KlingEvolve, #KlingSelect, and #TuLibs (tumor libraries) ➡️www.klingbio.com #antibodytherapeutics #cancer #oncology #immunotherapy #immunooncology

🌏Global Bispecific Antibody Landscape | Vol.16 — #Ivonescimab (PD-1 × VEGF-A) 🧠 Approved in May 2024, Ivonescimab represents a breakthrough in dual immune checkpoint × angiogenesis inhibition, targeting PD-1 and VEGF-A simultaneously. 🧠 By combining immune activation with anti-angiogenic blockade, it offers a synergistic approach against solid tumors and respiratory diseases. ▶ #Bioworkshops specializes in bispecific and multispecific antibodies, offering: Flexible molecular design (symmetric, asymmetric, IgG-like) High-yield expression systems End-to-end development from design to GMP manufacturing.  📖 Reference 1. https://lnkd.in/eNnMGrfh. 2. https://lnkd.in/gy8kectQ. 3. Wikipedia-Ivonescimab.

In 2022, we collaborated with the laboratory of Dr. Jamie Spangler to engineer a fusion protein combining anti-human IgG with invertase, enabling the use of glucometers to quantify antibody levels in SARS-CoV-2 patient samples (https://lnkd.in/eURkViv7). In 2023, this reagent was used to measure antibody doses in convalescent plasma that successfully prevented acute infection in patients (https://lnkd.in/eTtwv_FZ). While analytically powerful, our original approach required manual handling and functionalized test strips, making it cumbersome for high-throughput applications. Now, we’re excited to share our latest advancement: 🔬 Elysse Ornelas-Gatdula and Xinran An have adapted the glucometer assay to a 96-well plate format, paving the way for scalable and automated antibody detection workflows. This new manuscript is detailed enough to serve as a methods paper, and we hope it proves useful for integrating into your own ELISA-based assays. Importantly, our fusion reporter binds any human IgG, making the assay broadly applicable beyond SARS-CoV-2. Stay tuned! Automation and enhanced sensing capabilities are on the horizon! 📄 Read the full article here: https://lnkd.in/eN8bEG5Y

💭 Engineering T cells to express chimeric antigen receptors (CARs) offers an attractive route for targeted immunotherapy. However, the extreme costs and specialised facilities required for manufacturing these products can severely limit their application. 💡Recently, LNP-mRNA technology has emerged as a cost-effective strategy for transient CAR T cell generation for both in vivo and ex vivo applications. Here, at Discovery | Charles River our expert scientific team have validated an in vitro platform for evaluating LNP-mRNA CARs with primary human T cells. This includes the assessment of transfection efficiency, and the CAR T cells ability to mediate tumour cell killing with functional assays. These approaches can be used to screen therapeutics and help accelerate candidates towards the next generation of cell therapies. ➡️ Please get in touch for more information. #CharlesRiverLaboratories #CRL #CRO #Immunology #Immunotherapy #CellTherapy #mRNA #LNP #CART #Tcell